Curated News
By: NewsRamp Editorial Staff
December 17, 2025
CleanGo Acquires Italian Plant-Based Pharma Leader Freia
TLDR
- CleanGo Innovations acquires Freia Farmaceutici to gain a competitive edge in the global health sector with plant-based therapeutics and access to European markets.
- CleanGo's subsidiary Kubera will acquire Freia through a share exchange of up to 25 million shares, subject to due diligence and regulatory approvals within 45 days.
- This acquisition promotes sustainable, plant-based therapeutic solutions with no known side effects, advancing ethical healthcare and disease prevention globally.
- Freia's ALFALIFE brand uses vegetable omegas to treat cardiovascular diseases and child neuropsychiatry, while their aesthetic line targets healthy skin solutions.
Impact - Why it Matters
This acquisition represents a significant convergence of sustainability and healthcare, potentially accelerating the availability of plant-based therapeutic solutions in North American markets. For consumers, it means greater access to scientifically-backed, natural alternatives for conditions ranging from cardiovascular disease to dermatological issues, with products that emphasize ethical sourcing and minimal side effects. The deal also signals growing corporate recognition that environmental responsibility and health innovation are complementary business strategies, potentially inspiring similar cross-industry partnerships that could reshape both the cleaning products and nutraceutical sectors.
Summary
CleanGo Innovations Inc., a Canadian publicly traded company specializing in eco-friendly cleaning solutions, has announced a strategic move through its subsidiary Kubera Black Technology Inc. to acquire Freia Farmaceutici Srl, an Italian leader in plant-based therapeutics. This non-binding Letter of Intent, dated December 16, 2025, represents a significant expansion into the global health sector for CleanGo, leveraging Freia's expertise in vegetable omegas and sustainable medical products. The transaction involves Freia shareholders receiving up to 25 million common shares of Kubera, with the resulting company continuing Freia's business under a board dominated by Freia nominees, while CleanGo maintains one director position.
Freia Farmaceutici, established in 2009 and headquartered in Milan, has built a reputation as an expert in vegetable omegas, with its ALFALIFE brand showing anti-inflammatory properties applicable to cardiovascular diseases, obesity, and child neuropsychiatry. The company's product portfolio includes CE-marked Class IIA medical devices under the Dermolife line for dermatological conditions, nutritional supplements, and aesthetic medicine solutions through its PROMEDIAL brand. With 2024 gross revenue exceeding €3.1 million entirely from the Italian market and positive growth projected for 2025, Freia brings both financial stability and scientific credibility to the partnership, including promising clinical trials for products targeting multiple sclerosis.
The acquisition promises to transform CleanGo's market position by integrating Freia's innovative plant-based therapeutic solutions into its portfolio, particularly in the rapidly growing nutraceutical and aesthetic medicine sectors. Freia's expansion strategy, which previously focused on European markets, will gain immediate access to North American markets through CleanGo's corporate structure. The transaction remains subject to due diligence, definitive agreement negotiation within 45 days, and regulatory approvals, but represents a calculated bet on the convergence of sustainability and healthcare innovation. For more details, view the original release on www.newmediawire.com.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, CleanGo Acquires Italian Plant-Based Pharma Leader Freia
